{"id":"tdf-3tc-efv-or-dtg-or-nvp","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness (EFV)"},{"rate":null,"effect":"Rash (NVP)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Renal impairment (TDF)"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TDF (tenofovir) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that prevent HIV reverse transcriptase from converting viral RNA to DNA. EFV (efavirenz) and NVP (nevirapine) are non-nucleoside reverse transcriptase inhibitors that directly inhibit the same enzyme through a different mechanism. DTG (dolutegravir) is an integrase inhibitor that prevents viral DNA from integrating into the host genome. These agents are used in combination to suppress HIV replication and prevent resistance.","oneSentence":"This is a combination antiretroviral regimen containing nucleoside reverse transcriptase inhibitors (TDF/3TC), a non-nucleoside reverse transcriptase inhibitor (EFV or NVP), or an integrase strand transfer inhibitor (DTG) that blocks HIV replication by inhibiting key viral enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:18.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment and suppression"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":"Bone Loss","enrollment":330},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7449,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TDF/3TC/EFV or DTG or NVP","genericName":"TDF/3TC/EFV or DTG or NVP","companyName":"MU-JHU CARE","companyId":"mu-jhu-care","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination antiretroviral regimen containing nucleoside reverse transcriptase inhibitors (TDF/3TC), a non-nucleoside reverse transcriptase inhibitor (EFV or NVP), or an integrase strand transfer inhibitor (DTG) that blocks HIV replication by inhibiting key viral enzymes. Used for HIV-1 infection treatment and suppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}